TauRx’s late-stage clinical trial reaches new milestone
TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer’s Disease (AD) research, has announced that the last patient has completed treatment in the blinded phase of their late-stage phase three clinical trial, Lucidity.
This significant milestone means TauRx will now progress to the data cleaning and analysis phase which enables the company to determine top line results on the safety and efficacy of Hydromethylthionine mesylate (which TauRx refers to under the chemical abbreviation, HMTM). The top line results are due to be announced in May.
Professor Claude Wischik, Executive Chairman and Co-Founder of TauRx, said: “AD is a leading cause of death in the UK and one of the world’s greatest unmet medical needs. At TauRx, we have focused our efforts over the last few decades to developing an effective treatment for this devastating disease based on targeting the tau pathology which is the main driver of clinical dementia.
“This milestone takes us one step closer to announcing the top line results of our potentially ground-breaking Lucidity study. We are extremely grateful to all who are progressing the trial; the study coordinators and investigators, and most importantly the patients who have volunteered to take part.”
According to Alzheimer’s Disease International, an estimated 50 million people are affected by dementia worldwide, and this is set to rise to 152 million by 2050 – with AD being the most common form.
Lucidity is the only late-stage clinical trial specifically targeting the tau pathology of AD. Aggregation of abnormal tau protein is one of the hallmark pathologies of AD. Tau aggregation and the subsequent formation of tau tangles disrupt neuronal function, a process that begins years before symptoms of dementia are seen. Tau pathology correlates strongly with AD severity and the clinical decline commonly seen in patients as loss of memory and ability to care for themselves.
Leona Minellas
Communication Director
07311 823947
Leona.minellas@aspectreputation.com
